TABLE 2.
Evaluation of dose to OAR for all ten prostate SBRT patients for both plans. Prescription was 36.25 Gy in five fractions.
| Dose to OAR | Parameters (Gy) | Halcyon VMAT | Truebeam VMAT | RTOG‐0938 criteria (Gy) |
|---|---|---|---|---|
| Rectum | D1cc | 32.25 ± 4.77 (25.38–36.65) | 32.46 ± 4.55 (23.62–36.73) | ≤ 38.06 |
| D3cc | 29.29 ± 5.48 (22.03–34.33) | 29.73 ± 4.86 (21.39–36.05) | ≤ 34.40 | |
| D90% | 25.57 ± 4.77 (20.05–32.48) | 26.05 ± 4.38 (21.28–32.54) | ≤ 32.63 | |
| D80% | 21.13 ± 3.43 (16.92–26.93) | 22.04 ± 3.49 (17.14–27.80) | ≤ 29.00 | |
| D50% | 12.77 ± 4.26 (4.59–17.26) | 13.39 ± 4.88 (3.83–18.18) | ≤ 18.13 | |
| Bladder | D1cc | 37.18 ± 0.24 (36.84–37.63) | 37.28 ± 0.29 (36.81–37.79) | ≤ 38.06 |
| D90% | 22.67 ± 9.22 (3.02–31.48) | 22.51 ± 9.44 (2.69–32.48) | ≤ 32.63 | |
| D50% | 3.50 ± 2.64 (0.45–7.72) | 3.29 ± 2.39 (0.39–7.91) | ≤ 18.13 | |
| Penile bulb | D0.03cc | 18.57 ± 15.45 (1.65–36.15) | 17.91 ± 15.43 (1.69–36.21) | ≤ 36.25 |
| D3cc | 4.43 ± 4.03 (1.24–12.06) | 3.98 ± 3.44 (1.27–11.19) | ≤ 20.00 | |
| Femoral heads | D10cc | 13.03 ± 1.65 (10.92–16.20) | 12.83 ± 1.35 (10.58–15.45) | ≤ 20.00 |
| Skin | D0.03cc | 11.45 ± 1.27 (9.25–12.97) | 11.57 ± 0.75 (10.42–12.86) | ≤ 30.00 |
| Urethra | D0.03cc | 37.26 ± 0.45 (36.63–37.89) | 37.29 ± 0.42 (36.59–37.66) | ≤ 38.78 |
Mean ± SD (range) was reported. None of the OAR parameters evaluated show statistically significant differences.